ScreenerHero
CPHCipher Pharmaceuticals Inc.
TSX · CA · Healthcare · Drug Manufacturers - Specialty & Generic · cipherpharma.com
14.34CAD+0.14%Mkt Cap: 265.05M $P/E: 9.24

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and r…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$65.19BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$15.34BUSDP/E 117.3
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
SFZN
Siegfried Holding AG
$4.01BUSDP/E 20.9
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
HIK
Hikma Pharmaceuticals PLC
$3.69BUSDP/E 12.7
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.32BUSDP/E 16.5
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD

Key Statistics

Company
Market Cap265.05M $
Enterprise Value258.68M $
Revenue (TTM)36.14M $
Gross Profit29.44M $
Net Income (TTM)19.90M $
Revenue/Share1.425 USD
Last Price14.34 CAD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees—
CountryCA
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)9.24
P/E (Forward)12.56
PEG—
EV/EBITDA13.41
EV/Revenue7.16
P/S7.33
P/B2.06
EPS (TTM)1.56
EPS (Forward)—
52W Range
12.4823% of range20.56
52W High20.56 CAD
52W Low12.48 CAD
Profitability
Gross Margin80.12%
Oper. Margin39.23%
EBITDA Margin53.36%
Profit Margin54.17%
ROE21.65%
ROA17.46%
Growth
Revenue Growth-9.80%
Earnings Growth-31.80%
Cash Flow & Leverage
Operating CF21.65M $
CapEx (TTM)146.38K $
FCF Margin38.72%
FCF Yield5.28%
Net Debt-6.37M $
Net Debt/EBITDA-0.33
Balance Sheet
Debt/Equity0.04
Current Ratio1.59
Quick Ratio1.09
Book Value/Sh6.952 CAD
Cash/Share0.3580 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CAD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.8 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)19.95 CAD
Upside (mean)+39.1%
Target Range17.00 CAD – 22.00 CAD
CAD17.00+39.1% to meanCAD22.00
# Analysts4
Ownership
Shares Out.25.42M
Float14.84M
Insiders42.35%
Institutions1.30%
Short Interest
Short Ratio2.7d
Short % Out.0.15%
Shares Short40.27K
Short (prev mo.)71.78K
Technical
SMA 5016.33 (-12.2%)
SMA 20015.98 (-10.2%)
Beta0.46
S&P 52W Chg18.16%
Avg Vol (30d)41.13K
Avg Vol (10d)102.47K
Technical Indicators
RSI (14)32.5
MACD-0.5591
MACD Signal-0.2351
MACD Hist.-0.3241
BB Upper18.77 CAD
BB Middle16.19 CAD
BB Lower13.61 CAD
BB Width31.89%
ATR (14)0.7386 CAD
Vol Ratio (20d)0.94x